LOS ANGELES, March 21 — The magnitude and quality of a key immune cell's response to vaccination with two doses of the Pfizer-BioNTech Covid-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, according to a new study published on Monday.